SLCO1B1基因多态性与阿托伐他汀的安全性及有效性相关性分析

Study on Association Between SLCO1B1 Genetic Polymorphisms and Efficacy and Safety of Atorvastatin

目的研究高脂血症患者SLCO1B1基因多态性与阿托伐他汀安全性及有效性的相关性。方法收集金华市人民医院2017年4月—2018年4月在门诊确诊为高脂血症患者的基本资料,测定纳入患者的SLCO1B1 c.388A>G和c.521T>C的基因多态性,定期随访受试者,并定期测定其甘油三酯、胆固醇、低密度脂蛋白胆固醇及肌酸激酶等相关实验室检查指标。结果纳入患者SLCO1B1 c.388A>G和c.521T>C等位基因频率分别为72.8%和15.9%。随访期结束后不同基因型患者的血清血脂指标变化率无明显差异。SLCO1B1c.521T>C基因多态性与阿托伐他汀的安全性有相关性(P=0.005)。结论SLCO1B1c.388A>G基因多态性对阿托伐他汀降脂疗效及安全性无影响。SLCO1B1 c.521T>C基因多态性与阿托伐他汀的降脂疗效无相关性,但对其安全性有一定影响。

OBJECTIVE To investigate the association between efficacy and safety of atorvastatin and SLCO1 B1 gene polymorphisms in hyperlipidemia patients.METHODS The basic information of the patients diagnosed with hyperlipidemia in outpatient clinics of Jinhua People’s Hospital in April 2017-April 2018 was collected.The genetic polymorphisms of SLCO1 B1 c.388 A>G and c.521 T>C were included in the patients.Regular follow-up test was conducted,and the related laboratory indexes of triglyceride,cholesterol,low density lipoprotein cholesterol and creatine kinase were measured regularly.RESULTS The frequency distributions of SLCO1 B1 c.388 A>G and c.521 T>C alleles in patients were 72.8%and 15.9%,respectively.At the end of the follow-up period,there was no significant difference in the rate of serum lipid changes among patients with different genotypes.The polymorphisms of SLCO1 B1 c.521 T>C gene was associated with the safety of atorvastatin(P=0.005).CONCLUSION The polymorphism of SLCO1 B1 c.388 A>G gene has no effect on the efficacy and safety of atorvastatin in lipid lowering.The polymorphism of SLCO1 B1 c.521 T>C gene has no correlation with the lipid-lowering effect of atorvastatin,but it has certain influence on its safety.